Deprivation of Growth Hormone-Releasing Hormone Early in the Rat’s Neonatal Life Permanently Affects Somatotropic Function
- 1 October 1990
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 127 (4) , 1625-1634
- https://doi.org/10.1210/endo-127-4-1625
Abstract
This work investigated in rats whether passive immunization against the endogenous GHRF in the early postnatal period led to permanent alterations of somatotropic function, similar to those observed in several human growth disorders, e.g. constitutional growth delay (CGD). On postnatal days 1, 2, 4, 6, 8, and 10, rats were given an anti-GHRF-serum (GHRH-Ab, 100 μ1/rat, sc) and were tested 1, 30, and 60 days after this treatment for basal and GHRHstimulated GH secretion both in vivo and in vitro. GHRH-Ab reduced both basal and GHRF-stimulated GH secretion at all intervals and induced marked and chronic impairment of growth rate. The following differences were observed in the GHRH-Abtreated rats compared to normal rabbit serum-treated controls: 1) GH biosynthesis (incorporation of L-[3H]leucine into the electrophoretic band of GH): reduction of about 70%, 1 day but not 30 days after treatment ; 2) Pituitary weight: significant reduction in absolute weight (30–40%) at all posttreatment intervals, and relative weight, 1 and 30 days after treatment. 3) Pituitary GH concentration: significant reduction in GH content (about 40%) but not concentration, at all posttreatment intervals; 4) Percentage of somatotrophs (immunocytochemistry): about 40% reduction 1 day, but not 30 and 60 days after treatment; 5) Hypothalamic somatostatin messenger RNA (mRNA) levels in situ hybridization): selective reduction (40%) in the periventricular nucleus 1 day but not 30 days after treatment; 6) Hypothalamic somatostatin cell number (immunocytochemistry): no significant changes in any hypothalamic area at any interval; 7) Pituitary somatostatin binding (in situ auto radiography): significant reduction, 1 day and 30 days after treatment; 8) Somatostatin inhibition of GH release “in vitro”: somatostatin effect on GH release was reduced 30 days after treatment. These and previous data indicate that: 1) Transient deprivation of GHRF in the immediate postnatal period of the rat leads to permanent impairment of growth rate and somatotropic function; 2) GHRF deficiency itself or through reduction of GH secretion impairs somatostatin functions temporarily in the hypothalamus and permanently in the pituitary; 3) This rat model may mimic some forms of growth disorders in humans and holds promise as useful tools for investigating the underlying pathophysiological mechanisms. (Endocrinology127: 1625–1634, 1990Keywords
This publication has 33 references indexed in Scilit:
- Fetal Rat Somatotropesin Vitro: Effects of Insulin, Cortisol, and Growth Hormone-Releasing Factor on Their Differentiation: A Light and Electron Microscopic Study*Endocrinology, 1984
- Ontogeny of Liver Somatotropic and Lactogenic Binding Sites in Male and Female Rats*Endocrinology, 1983
- EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCYThe Lancet, 1983
- The Ontogeny of Somatotropic Binding Sites in Ovine Hepatic Membranes*Endocrinology, 1983
- Effect on Growth of Prolactin Deficiency Induced in Infant Mice*Endocrinology, 1982
- High affinity binding sites for somatostatin to rat pituitaryBiochemical and Biophysical Research Communications, 1982
- Measurement of Somatomedin-Related Peptides in Fetal, Neonatal, and Maternal Rat Serum by Insulin-Like Growth Factor (IGF) I Radioimmunoassay, IGF-II Radioreceptor Assay (RRA), and Multiplication- Stimulating Activity RRA after Acid-Ethanol Extraction*Endocrinology, 1982
- INTRAVENTRICULARLY INJECTED GROWTH HORMONE STIMULATES SOMATOSTATIN RELEASE INTO RAT HYPOPHYSIAL PORTAL BLOODEndocrinology, 1981
- Hormonal Control of Growth in the Infant Rat*Endocrinology, 1981
- Fluorographic detection of radioactivity in polyacrylamide gols with the water-soluble fluor, sodium salicylateAnalytical Biochemistry, 1979